[Form 4] Guardant Health, Inc. Insider Trading Activity
John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership on 09/01/2025. He received 264 restricted stock units that vested (reported as 264 shares acquired at $0), increasing his holdings to 45,087 shares. On the same date he disposed of 139 shares at a reported price of $67.42, leaving 44,948 shares beneficially owned after the transactions. The disclosure notes the RSU award was granted on November 2, 2021, with an initial 25% vesting on September 1, 2022, and the remaining 75% vesting quarterly over the following three years.
John G. Saia, Chief Legal Officer di Guardant Health, Inc. (GH), ha segnalato variazioni nella propriet脿 beneficiaria il 01/09/2025. In tale data gli sono state attribuite 264 unit脿 azionarie vincolate (RSU) divenute pienamente esigibili 鈥� riportate come 264 azioni acquisite a $0 鈥� portando il suo totale a 45.087 azioni. Nello stesso giorno ha ceduto 139 azioni a un prezzo segnalato di $67,42, rimanendo con 44.948 azioni dopo le operazioni. La comunicazione specifica che la concessione delle RSU risale al 2 novembre 2021, con il 25% iniziale maturato il 1掳 settembre 2022 e il restante 75% che matura trimestralmente nei tre anni successivi.
John G. Saia, Chief Legal Officer de Guardant Health, Inc. (GH), inform贸 cambios en la propiedad beneficiaria el 01/09/2025. Ese d铆a recibi贸 264 unidades de acciones restringidas (RSU) que se hicieron efectivas 鈥� reportadas como 264 acciones adquiridas a $0 鈥� elevando su tenencia a 45.087 acciones. En la misma fecha, enajen贸 139 acciones a un precio informado de $67,42, quedando con 44.948 acciones tras las transacciones. La divulgaci贸n indica que la adjudicaci贸n de las RSU se realiz贸 el 2 de noviembre de 2021, con un 25% inicial que se consolid贸 el 1 de septiembre de 2022 y el 75% restante consolid谩ndose trimestralmente durante los tres a帽os siguientes.
John G. Saia, Guardant Health, Inc. (GH) 氩曤毂呾瀯鞛�(Chief Legal Officer),電� 2025雲� 9鞗� 1鞚检棎 鞙犾澋靻岇湢甓� 氤�霃欖潉 鞁犼碃頄堨姷雼堧嫟. 攴鸽偁 攴鸽姅 264欤检潣 鞝滍暅順� 欤检嫕雼渼(RSU)臧� 頇曥爼霅橃柎(氤搓碃靸� 264欤� 旆摑, 旆摑臧� $0) 氤挫湢霟夓澊 45,087欤茧 歃濌皜頄堨姷雼堧嫟. 臧欖潃 雮� 攴鸽姅 氤搓碃臧�鞎� $67.42鞐� 139欤茧ゼ 觳橂秳頃橃棳 瓯半灅 頉� 鞙犾澋靻岇湢 欤检嫕 靾橂姅 44,948欤缄皜 霅橃棃鞀惦媹雼�. 瓿奠嫓鞐愲姅 頃措嫻 RSU 攵�鞐澕鞚� 2021雲� 11鞗� 2鞚检澊氅�, 齑堦赴 25%電� 2022雲� 9鞗� 1鞚检棎 頇曥爼霅橁碃 雮橂ǜ歆� 75%電� 鞚错泟 3雲� 霃欖晥 攵勱赴氤勲 頇曥爼霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
John G. Saia, Chief Legal Officer de Guardant Health, Inc. (GH), a d茅clar茅 des changements de propri茅t茅 b茅n茅ficiaire le 01/09/2025. Il a re莽u 264 unit茅s d'actions restreintes (RSU) qui ont vest茅 鈥� d茅clar茅es comme 264 actions acquises 脿 $0 鈥� portant sa d茅tention 脿 45 087 actions. Le m锚me jour, il a c茅d茅 139 actions 脿 un prix d茅clar茅 de $67,42, restant d茅tenteur de 44 948 actions apr猫s les op茅rations. La divulgation pr茅cise que l'attribution des RSU a 茅t茅 faite le 2 novembre 2021, avec un premier versement de 25 % le 1er septembre 2022 et les 75 % restants acqu茅rant des droits trimestriellement au cours des trois ann茅es suivantes.
John G. Saia, Chief Legal Officer von Guardant Health, Inc. (GH), meldete am 01.09.2025 脛nderungen in seinem wirtschaftlichen Eigentum. An diesem Tag wurden ihm 264 Restricted Stock Units (RSU) ausgegeben, die vesteten 鈥� gemeldet als 264 erworbene Aktien zu $0 鈥� wodurch sein Bestand auf 45.087 Aktien anwuchs. Am selben Tag ver盲u脽erte er 139 Aktien zu einem gemeldeten Preis von $67,42 und hielt nach den Transaktionen 44.948 Aktien. Die Offenlegung weist darauf hin, dass die RSU-Zuteilung am 2. November 2021 erfolgte, mit einer ersten Vesting-Rate von 25 % am 1. September 2022 und den verbleibenden 75 %, die in den folgenden drei Jahren viertelj盲hrlich vesten.
- Vesting of 264 RSUs increased the reporting person鈥檚 direct ownership, reflecting employee compensation realization
- Clear disclosure of the original grant date and vesting schedule provides transparency
- Disposition of 139 shares at $67.42 reduced direct holdings, representing a small insider sale
Insights
TL;DR: Insider received vested RSUs and sold a small number of shares; overall change is minor and routine.
The filing shows a routine vesting event and a small disposition by the Chief Legal Officer. Acquisition of 264 vested RSUs increased direct ownership to 45,087 shares before the sale. The sale of 139 shares at $67.42 reduced holdings to 44,948 shares. These transactions reflect standard compensation vesting and a small liquidity event rather than a material shift in ownership or company control.
TL;DR: Transactions are compensation-related vesting and a minor sale; governance implications are limited.
The Form 4 discloses compensation-driven vesting from a 2021 RSU grant and a contemporaneous small disposal. The vesting schedule described is standard (25% then quarterly vesting over three years). There is no indication of acceleration, pledge, or change in relationship to the issuer. From a governance perspective, these are routine insider transactions with no apparent red flags.
John G. Saia, Chief Legal Officer di Guardant Health, Inc. (GH), ha segnalato variazioni nella propriet脿 beneficiaria il 01/09/2025. In tale data gli sono state attribuite 264 unit脿 azionarie vincolate (RSU) divenute pienamente esigibili 鈥� riportate come 264 azioni acquisite a $0 鈥� portando il suo totale a 45.087 azioni. Nello stesso giorno ha ceduto 139 azioni a un prezzo segnalato di $67,42, rimanendo con 44.948 azioni dopo le operazioni. La comunicazione specifica che la concessione delle RSU risale al 2 novembre 2021, con il 25% iniziale maturato il 1掳 settembre 2022 e il restante 75% che matura trimestralmente nei tre anni successivi.
John G. Saia, Chief Legal Officer de Guardant Health, Inc. (GH), inform贸 cambios en la propiedad beneficiaria el 01/09/2025. Ese d铆a recibi贸 264 unidades de acciones restringidas (RSU) que se hicieron efectivas 鈥� reportadas como 264 acciones adquiridas a $0 鈥� elevando su tenencia a 45.087 acciones. En la misma fecha, enajen贸 139 acciones a un precio informado de $67,42, quedando con 44.948 acciones tras las transacciones. La divulgaci贸n indica que la adjudicaci贸n de las RSU se realiz贸 el 2 de noviembre de 2021, con un 25% inicial que se consolid贸 el 1 de septiembre de 2022 y el 75% restante consolid谩ndose trimestralmente durante los tres a帽os siguientes.
John G. Saia, Guardant Health, Inc. (GH) 氩曤毂呾瀯鞛�(Chief Legal Officer),電� 2025雲� 9鞗� 1鞚检棎 鞙犾澋靻岇湢甓� 氤�霃欖潉 鞁犼碃頄堨姷雼堧嫟. 攴鸽偁 攴鸽姅 264欤检潣 鞝滍暅順� 欤检嫕雼渼(RSU)臧� 頇曥爼霅橃柎(氤搓碃靸� 264欤� 旆摑, 旆摑臧� $0) 氤挫湢霟夓澊 45,087欤茧 歃濌皜頄堨姷雼堧嫟. 臧欖潃 雮� 攴鸽姅 氤搓碃臧�鞎� $67.42鞐� 139欤茧ゼ 觳橂秳頃橃棳 瓯半灅 頉� 鞙犾澋靻岇湢 欤检嫕 靾橂姅 44,948欤缄皜 霅橃棃鞀惦媹雼�. 瓿奠嫓鞐愲姅 頃措嫻 RSU 攵�鞐澕鞚� 2021雲� 11鞗� 2鞚检澊氅�, 齑堦赴 25%電� 2022雲� 9鞗� 1鞚检棎 頇曥爼霅橁碃 雮橂ǜ歆� 75%電� 鞚错泟 3雲� 霃欖晥 攵勱赴氤勲 頇曥爼霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
John G. Saia, Chief Legal Officer de Guardant Health, Inc. (GH), a d茅clar茅 des changements de propri茅t茅 b茅n茅ficiaire le 01/09/2025. Il a re莽u 264 unit茅s d'actions restreintes (RSU) qui ont vest茅 鈥� d茅clar茅es comme 264 actions acquises 脿 $0 鈥� portant sa d茅tention 脿 45 087 actions. Le m锚me jour, il a c茅d茅 139 actions 脿 un prix d茅clar茅 de $67,42, restant d茅tenteur de 44 948 actions apr猫s les op茅rations. La divulgation pr茅cise que l'attribution des RSU a 茅t茅 faite le 2 novembre 2021, avec un premier versement de 25 % le 1er septembre 2022 et les 75 % restants acqu茅rant des droits trimestriellement au cours des trois ann茅es suivantes.
John G. Saia, Chief Legal Officer von Guardant Health, Inc. (GH), meldete am 01.09.2025 脛nderungen in seinem wirtschaftlichen Eigentum. An diesem Tag wurden ihm 264 Restricted Stock Units (RSU) ausgegeben, die vesteten 鈥� gemeldet als 264 erworbene Aktien zu $0 鈥� wodurch sein Bestand auf 45.087 Aktien anwuchs. Am selben Tag ver盲u脽erte er 139 Aktien zu einem gemeldeten Preis von $67,42 und hielt nach den Transaktionen 44.948 Aktien. Die Offenlegung weist darauf hin, dass die RSU-Zuteilung am 2. November 2021 erfolgte, mit einer ersten Vesting-Rate von 25 % am 1. September 2022 und den verbleibenden 75 %, die in den folgenden drei Jahren viertelj盲hrlich vesten.
FAQ
Who filed this Form 4 for Guardant Health (GH)?
What transactions did John G. Saia report on 09/01/2025?
How many Guardant Health shares does Saia beneficially own after these transactions?
When was the restricted stock unit award granted and what was its vesting schedule?
Do these transactions indicate a change in control or significant ownership shift?
